CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 10 clinical trials at NIH that match your search criteria

Cancer by type/disease: Lymphoma (Childhood)

Trial and Protocol Number Lymphoma	Principal Investigator	Referral Contact
Phase II
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas NCI-04-C-0173	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov

Trial and Protocol Number Lymphomatoid Granulomatosis	Principal Investigator	Referral Contact
Phase II
Treatment and Natural History Study of Lymphomatoid Granulomatosis NCI-94-C-0074	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

Trial and Protocol Number AIDS Related Cancers	Principal Investigator	Referral Contact
Phase II
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281	Steven Z. Pavletic 301-402-4899	Caroline Stewart 301-451-6569 cstewartv@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase I/II
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies NCI-01-C-0125	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL) NCI-08-C-0123	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Leukemia	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia NCI-00-C-0030	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase I
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.